Latest news with #JohnsonJohnson
New York Times
2 days ago
- Business
- New York Times
From No Hope to a Potential Cure for a Deadly Blood Cancer
A group of 97 patients had longstanding multiple myeloma, a common blood cancer that doctors consider incurable, and faced a certain, and extremely painful, death within about a year. They had gone through a series of treatments, each of which controlled their disease for a while. But then it came back, as it always does. They reached the stage where they had no more options and were facing hospice. They all got immunotherapy, in a study that was a last-ditch effort. A third responded so well that they got what seems to be an astonishing reprieve. The immunotherapy developed by Legend Biotech, a company founded in China, seems to have made their cancer disappear. And after five years, it still has not returned in those patients — a result never before seen in this disease. These results, in patients whose situation had seemed hopeless, has led some battle-worn American oncologists to dare to say the words 'potential cure.' 'In my 30 years in oncology, we haven't talked about curing myeloma,' said Dr. Norman Sharpless, a former director of the National Cancer Institute who is now a professor of cancer policy and innovation at the University of North Carolina School of Medicine. 'This is the first time we are really talking seriously about cure in one of the worst malignancies imaginable.' The new study, reported Tuesday at the annual conference of the American Society of Clinical Oncology and published in The Journal of Clinical Oncology, was funded by Johnson & Johnson, which bought Legend Biotech. Want all of The Times? Subscribe.
Associated Press
4 days ago
- Business
- Associated Press
Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer
Pasritamig, a first-in-class bispecific T-cell-engaging antibody, shows potential in mCRPC with outpatient dosing designed for the community setting Data show low rates of treatment-related adverse events, signaling human kallikrein 2 (KLK2) as a novel, highly specific target CHICAGO, June 1, 2025 /PRNewswire/ -- Johnson & Johnson announced today new data from a Phase 1 study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific antibody that activates T-cells to harness the body's immune system against prostate cancer cells, showing promise in patients with advanced disease who have progressed after multiple lines of therapy. These first data on pasritamig, from the first-in-human study, demonstrate that pasritamig appears well-tolerated and exhibits a promising antitumor activity in patients with metastatic castration-resistant prostate cancer (mCRPC), highlighting the potential of KLK2 as a novel target for T-cell engagement in advanced disease.1 These data were presented as an oral presentation (Abstract #5017) at the 2025 American Society of Clinical Oncology Annual Meeting and published simultaneously in The Journal of Clinical Oncology. Pasritamig is a novel T-cell engager designed to bind both CD3 on T-cells and KLK2—a prostate-specific antigen with minimal expression outside of the prostate. Pasritamig activates T-cells by binding to CD3 and directing them to KLK2- expressing tumor cells, engaging the body's immune system to specifically target these cancerous cells. This differentiated approach aims to deliver a targeted treatment for patients with advanced prostate cancer, while potentially reducing the high-grade toxicities historically associated with T-cell engagers. 'These first-in-human results for pasritamig are highly encouraging, demonstrating that KLK2 is a viable target for T-cell engagers in metastatic castration-resistant prostate cancer,' said Capucine Baldini*, M.D., Ph.D., Drug Development Department (DITEP), Institut Gustave Roussy, and presenting author. 'The data show a promising safety profile, with manageable adverse events and no AEs leading to treatment discontinuations or ICANS observed, with 40 percent of patients having no treatment-related AEs at all. Given the limited treatment options for mCRPC, these findings support further investigation of pasritamig and the role of KLK2-targeted T-cell therapies as a potential new approach for patients with aggressive disease.' 'Metastatic castration-resistant prostate cancer remains one of the most difficult stages of prostate cancer to treat, particularly for patients who haven't responded well to previous treatments,' said Jeff Infante, M.D., Vice President of Early Clinical Development and Translational Research at Johnson & Johnson Innovative Medicine. 'This investigational approach underscores our commitment to developing innovative and practice-changing medicines that are well-tolerated and can be easily administered in community practice settings.' The Phase 1 first-in-human study ( NCT04898634 ) evaluated 174 patients with ages ranging from 36 to 89 years old and on average having received four prior therapies (range 1-13). The recommended phase 2 dose (RP2D) of pasritamig was 3.5mg on day 1, 18mg on day 8, 300mg intravenously on day 15 and then once every six weeks. The RP2D safety group also included patients treated once every three weeks as the toxicity profiles were very similar. The RP2D efficacy group only included patients treated at the RP2D once every six weeks.1 Within the RP2D safety group (n=45), treated once every three or six weeks, 100 percent had previously received androgen receptor pathway inhibitors, 75.6 percent had undergone taxane chemotherapy, and 37.8 percent had been treated with Lutetium 177 vipivotide tetraxetan prostate-specific membrane antigen radioligand therapy.1 The most common treatment- related adverse events (TRAEs) were Grade 1/2 infusion-related reactions (24.4 percent), Grade 1 cytokine release syndrome (CRS) presenting as fever only (8.9 percent, no steroid or tocilizumab was administered) and no reports of higher grade CRS. No TRAEs leading to treatment discontinuation or dose reduction were reported and no immune effector cell-associated neurotoxicity syndrome (ICANS) was observed. Grade 3 TRAEs were infrequent with 4.4 percent of patients reporting transient AST/ALT increases and neutropenia. There were no dose-limiting toxicities reported. The favorable safety profile of the RP2D regimen enabled convenient outpatient administration on a patient-friendly, once-every-six-weeks schedule.1 Of the patients in the RP2D efficacy group (n=33), treated once every six weeks, 42.4 percent achieved a 50 percent or greater reduction in their prostate-specific antigen (PSA) levels with a median rPFS of 7.9 months (95 percent confidence interval [CI] 2.9, not estimable [NE]) and 21.2 percent of patients continuing therapy. Treatment with pasritamig showed durable disease control and rPFS that compares favorably to historical data in heavily pretreated patients with mCRPC.1 Metastatic castration-resistant prostate cancer occurs in a significant portion of prostate cancer patients, with many progressing despite initial therapies.2 Overall survival from diagnosis of mCRPC patients ranges from 13.5 to 31.6 months, and lower in patients who have progressed on therapy.3 Treatment options remain limited, underscoring the urgent need for safer and more effective therapies.4 About Pasritamig (JNJ-78278343) Pasritamig (JNJ-78278343) is an investigational T-cell-engaging bispecific antibody (bsAb) targeting human kallikrein 2 (KLK2) on prostate cancer cells and CD3 on T-cells. This approach is being evaluated in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC), a patient population with limited treatment options. About Metastatic Castration-Resistant Prostate Cancer (mCRPC) Metastatic castration-resistant prostate cancer (mCRPC) is a challenging and aggressive stage of prostate cancer where the disease progresses despite androgen deprivation therapy.2 Patients often experience metastasis to bones and lymph nodes, leading to poor outcomes and limited treatment options, including chemotherapy and second-line hormone therapies.5 The median overall survival ranges from 13.5 to 31.6 months depending on the site of metastasis, with a typical range of 15–36 months across the broader population.3,6 Survival rates can vary significantly depending on factors such as prior treatment history, disease burden, and response to therapy. The need for more effective treatments is critical, as the disease continues to impact a large number of men globally, with mCRPC being responsible for a substantial number of prostate cancer-related deaths. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at or at Follow us at @JNJInnovMed. Janssen Research & Development, LLC, Janssen Biotech, Inc., Janssen Global Services, LLC and Janssen Scientific Affairs, LLC are Johnson & Johnson companies. Cautions Concerning Forward-Looking Statements This press release contains 'forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of JNJ-78278343. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned 'Cautionary Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Source: Johnson & Johnson *Dr. Capucine Baldini has provided consulting, advisory, and speaking services to Johnson & Johnson; Dr. Baldini has not been paid for any media work. 1 Baldini, C., et al. Phase 1 Study Results of Pasritamig (JNJ-78278343) in Metastatic Castration-Resistant Prostate Cancer. 2025 American Society of Clinical Oncology Annual Meeting. June 2025. 2 Scher, H. I., et al. (2016). 'Treatment of castration-resistant prostate cancer: Current and future strategies.' Nature Reviews Clinical Oncology, 13(10), 577-590. 3 Wallace KL, Landsteiner A, Bunner SH, Engel-Nitz NM, Luckenbaugh AN. Increasing prevalence of metastatic castration-resistant prostate cancer in a managed care population in the United States. Cancer Causes Control. 2021;32(12):1365-1374. doi:10.1007/s10552-021-01484-4 4 Ravi P, Mateo J, Lorente D, et al. Clinical prognostic factors and management of metastatic castration-resistant prostate cancer: a population-based study. PLoS One. 2015;10(10):e0139440. doi:10.1371/ 5 Ryan, C. J., et al. (2015). 'Abiraterone acetate in metastatic prostate cancer: A new era.' Journal of Clinical Oncology, 33(10), 1051-1060. 6 Kawahara, T., Saigusa, Y., Yoneyama, S. et al. Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide. BMC Cancer 23, 214 (2023). View original content to download multimedia: SOURCE Johnson & Johnson
The Independent
27-05-2025
- Entertainment
- The Independent
New Netflix doc explores the killer who put cyanide in the medicine cabinet
J ames Lewis eyes the Tylenol bottle placed in front of him. Once considered a suspect in the deaths of seven people who died in 1982 after taking the medication that had been laced with cyanide, Lewis was sitting for a rare on-camera interview with Netflix for a new docuseries, Cold Case: The Tylenol Murders . 'You think I'm going to open this and get my fingerprints all over it?' Lewis asks as he struggles to open the tamper-evident bottle seal. 'Everybody who tries to open these bottles swears my name,' he admits with a smile. Lewis eventually breaks through the seal with his long nails and rolls a capsule between his fingers. 'Well, they're considerably smaller than they used to be. I haven't had one of these in my hands for a long time.' After breaking it apart, he pushes it away and says, 'OK, let's put that away. That might scare people.' James Lewis, long regarded as the main suspect of the murders, sat down with the documentary makers for an interview before his death (Netflix) Before 1982, nobody thought twice about opening a bottle of Tylenol, but when seven people who took cyanide-laced medicine in the Chicago area died within a span of just a few days, it sparked panic, triggering a nationwide recall of the product. The poisonings eventually led to tamper proof packaging for over-the-counter medications. Lewis quickly emerged as a suspect after investigators determined that he had sent a letter to Johnson & Johnson, demanding $1 million to stop the Tylenol murders. But there was not enough evidence to charge him and he was instead convicted of attempted extortion and sentenced to 10 years in prison. 'They make it look like I'm the world's most horrible, dangerous person ever,' Lewis said in an interview with Netflix in 2023, not long before his death. 'And I wouldn't hurt anybody,' he then added with a chuckle. Nearly two years after Lewis' death at age 76, his interview, along with interviews with the victims' families and people close to the investigation, will be featured on Cold Case: The Tylenol Murders , which will be available to stream on May 26. But why now? 'Today, every tamper-proof seal is a reminder of that dark moment — when cyanide-laced capsules transformed an everyday medicine into a murder weapon, permanently reshaping consumer industries,' directors Yotam Guendelman and Ari Pines tell Netflix. 'For more than 40 years, this case has been viewed through a narrow lens, locked onto a single theory while crucial evidence and promising leads were left unexplored. Perhaps that's why, even after all these years, the case remains unsolved.' The 7 victims of the 'Tylenol Murders' The nightmare rash of deaths began on September 29, 1982 with a sick 12-year-old girl. Mary Kellerman, who lived in Elk Grove Village, Illinois, felt sick one morning, so she took a Tylenol. She died soon after. Later that same day, three members of the same family died after taking the medication. Adam Janus, 27, took two Tylenol capsules and died in a hospital. His brother Stanley Janus and Stanley's wife, Theresa, took Tylenol from the same bottle, and both were dead a short time later. New Netflix doc about the Tylenol Murders features the Janus family who died from taking cyanide-laced Tylenol in 1982 (Netflix) Over the next two days, three more people died, including Mary 'Lynn' Reiner, 27, who had just given birth to her fourth child; 31-year-old Mary McFarland; and 35-year-old Paula Prince. All seven victims lived in the Chicago suburbs. Their deaths led the Food and Drug Administration to introduce anti-tampering features such as foil seals and standardized packaging. Congress passed the 'Tylenol bill' in 1983 which made it a federal offense to tamper with packaging. Suspect in 'Tylenol Murders' dies in 2023 In July 2023, James Lewis was found dead in his Massachusetts home. He was 76 years old. His death frustrated law enforcement who had continued to pursue him over the cyanide poisoning deaths, which led to widespread panic and sweeping changes to the way prescription drugs were bought and sold. James Lewis is escorted through Boston's Logan Airport, Friday Oct. 13, 1995, after being released from the Federal Correctional Institution in Oklahoma. Lewis, the suspect in the 1982 Tylenol murders, was found dead Sunday, July 9, 2023 at his home (AP) Lewis was arrested in 1982 after a nationwide manhunt and served 12 years in federal prison for trying to extort the drug manufacturer. He later admitted sending the letter to Johnson & Johnson demanding the money to stop the murders, but he said he never intended to collect it. He said he wanted to embarrass his wife's former employer by having the money sent to the employer's bank account. Investigators have fruitlessly tried to prove for 40 years that Lewis wrote the letters before the poisonings took place. In a 1992 jailhouse interview with ABC 7 Chicago, Lewis described how the killer would have used a pegboard to drill holes into the Tylenol capsules and inject them with deadly cyanide. James Lewis provided detailed drawings showing how the Tylenol murders poisoner could have carried out the 1982 terror campaign (ABC7) Another suspect was identified as a dock worker named Roger Arnold after there were reports he had made threats to poison others. Arnold also had connections to some of the victims and allegedly kept cyanide in his home. He was ultimately ruled out by DNA evidence. No one has been officially charged with the fatal Tylenol poisonings.
Yahoo
24-05-2025
- Business
- Yahoo
Generating Passive Income: 3 Top Dow Dividend Stocks to Buy for 2025 and Beyond
Chevron has hiked its dividends for 38 straight years. Johnson & Johnson recently raised its dividend for the 63rd year in a row. Verizon has the longest dividend growth streak in the U.S. telecom sector. 10 stocks we like better than Chevron › The Dow Jones Industrial Average is an iconic stock market index. It tracks the performance of 30 of the country's most prominent publicly traded companies. Its components do get changed over time as new leaders rise and old ones fade, but as a rule, those that earn and keep a place in the Dow are some of the bluest of blue chip stocks. Most of these companies pay dividends. Some of these payouts are currently very attractive if you want to generate passive income. Chevron (NYSE: CVX), Johnson & Johnson (NYSE: JNJ), and Verizon (NYSE: VZ) stand out as the top Dow stocks to buy for income in 2025 and beyond. At its current share price, the dividend that Chevron pays now yields just over 5%. That's more than double the average yield of a Dow component, which was recently right below 2%. The oil giant has an excellent track record on dividends: It has raised its payments for 38 straight years, a time frame that included multiple commodity cycles. Moreover, Chevron didn't just provide modest increases to keep its streak alive; it has delivered peer-leading dividend growth over the past decade. Chevron should have no trouble continuing to grow its high-yielding dividend in the future. The company has the most resilient portfolio in the sector, with an industry-leading breakeven level of around $30 per barrel. It also has a strong balance sheet. Its leverage ratio is currently at 14%, which is below its 20% to 25% target range and at the low end of its peer group. Chevron management says it expects to boost its free cash flow by $9 billion by next year assuming oil averages $60 a barrel (around the current level) as it completes several growth projects. All of these factors suggest the company will have plenty of fuel to continue growing its dividend. Johnson & Johnson's dividend at its current share price yields around 3.4%. The healthcare giant recently hiked its payout by nearly 5%, extending its dividend growth streak to 63 straight years. That kept the company in the elite group of Dividend Kings, companies with 50 or more years of annual dividend increases. Johnson & Johnson has one of the healthiest financial profiles in the world. It's one of just two companies with an AAA bond rating, which is higher than the U.S. government. It ended the first quarter with a mere $13.5 billion of net debt ($38.8 billion of cash and $52.3 billion of debt) -- a pittance for a healthcare behemoth with a $370 billion market cap. Last year, Johnson & Johnson generated $20 billion in free cash flow, a $1.6 billion increase from the prior year. That easily covered its $11.8 billion dividend outlay. The company produced that robust free cash flow even though it invested more than $17 billion in research and development (R&D), making it one of the top R&D spenders across all industries. The company's financial strength also enabled it to invest over $30 billion in inorganic growth initiatives like acquisitions in the past year. Its pattern of heavy investments in pursuit of growth should result in rising cash flows that will enable it to keep increasing its dividend regularly. Verizon currently clocks in with the highest dividend yield in the Dow Jones at 6.2%. The telecom giant produces lots of recurring revenue to support that prodigious payout. Last year, Verizon generated $36.9 billion in cash flow from operations, more than enough to cover its capital expenditures ($17.1 billion) and dividend payment ($11.2 billion). The company used its excess free cash flow to strengthen its already solid balance sheet. It's putting some of that balance sheet strength to use to buy Frontier Communications in a $20 billion all-cash deal that should close in the next year. That acquisition will bolster its fiber network and should deliver at least $500 million in annual cost savings. Verizon also continues to invest heavily in organic capital projects to maintain and expand its broadband and mobile networks. These investments should grow the company's earnings and cash flow in the future. Verizon's increasing earnings should enable it to continue raising its dividend. It delivered its 18th consecutive annual dividend increase late last year, a move that maintained the longest current payout-hiking streak in the U.S. telecom sector. The Dow Jones Industrial Index can be a great place for investors to look for high-quality dividend stocks. Chevron, Johnson & Johnson, and Verizon have certainly been elite dividend payers over the years. With yields that are well above the market average and more dividend growth ahead, all three are great Dow stocks to buy for passive income in 2025 and beyond. Before you buy stock in Chevron, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Chevron wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $640,662!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $814,127!* Now, it's worth noting Stock Advisor's total average return is 963% — a market-crushing outperformance compared to 168% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Matt DiLallo has positions in Chevron, Johnson & Johnson, and Verizon Communications. The Motley Fool has positions in and recommends Chevron. The Motley Fool recommends Johnson & Johnson and Verizon Communications. The Motley Fool has a disclosure policy. Generating Passive Income: 3 Top Dow Dividend Stocks to Buy for 2025 and Beyond was originally published by The Motley Fool
Yahoo
24-05-2025
- Business
- Yahoo
Generating Passive Income: 3 Top Dow Dividend Stocks to Buy for 2025 and Beyond
Chevron has hiked its dividends for 38 straight years. Johnson & Johnson recently raised its dividend for the 63rd year in a row. Verizon has the longest dividend growth streak in the U.S. telecom sector. 10 stocks we like better than Chevron › The Dow Jones Industrial Average is an iconic stock market index. It tracks the performance of 30 of the country's most prominent publicly traded companies. Its components do get changed over time as new leaders rise and old ones fade, but as a rule, those that earn and keep a place in the Dow are some of the bluest of blue chip stocks. Most of these companies pay dividends. Some of these payouts are currently very attractive if you want to generate passive income. Chevron (NYSE: CVX), Johnson & Johnson (NYSE: JNJ), and Verizon (NYSE: VZ) stand out as the top Dow stocks to buy for income in 2025 and beyond. At its current share price, the dividend that Chevron pays now yields just over 5%. That's more than double the average yield of a Dow component, which was recently right below 2%. The oil giant has an excellent track record on dividends: It has raised its payments for 38 straight years, a time frame that included multiple commodity cycles. Moreover, Chevron didn't just provide modest increases to keep its streak alive; it has delivered peer-leading dividend growth over the past decade. Chevron should have no trouble continuing to grow its high-yielding dividend in the future. The company has the most resilient portfolio in the sector, with an industry-leading breakeven level of around $30 per barrel. It also has a strong balance sheet. Its leverage ratio is currently at 14%, which is below its 20% to 25% target range and at the low end of its peer group. Chevron management says it expects to boost its free cash flow by $9 billion by next year assuming oil averages $60 a barrel (around the current level) as it completes several growth projects. All of these factors suggest the company will have plenty of fuel to continue growing its dividend. Johnson & Johnson's dividend at its current share price yields around 3.4%. The healthcare giant recently hiked its payout by nearly 5%, extending its dividend growth streak to 63 straight years. That kept the company in the elite group of Dividend Kings, companies with 50 or more years of annual dividend increases. Johnson & Johnson has one of the healthiest financial profiles in the world. It's one of just two companies with an AAA bond rating, which is higher than the U.S. government. It ended the first quarter with a mere $13.5 billion of net debt ($38.8 billion of cash and $52.3 billion of debt) -- a pittance for a healthcare behemoth with a $370 billion market cap. Last year, Johnson & Johnson generated $20 billion in free cash flow, a $1.6 billion increase from the prior year. That easily covered its $11.8 billion dividend outlay. The company produced that robust free cash flow even though it invested more than $17 billion in research and development (R&D), making it one of the top R&D spenders across all industries. The company's financial strength also enabled it to invest over $30 billion in inorganic growth initiatives like acquisitions in the past year. Its pattern of heavy investments in pursuit of growth should result in rising cash flows that will enable it to keep increasing its dividend regularly. Verizon currently clocks in with the highest dividend yield in the Dow Jones at 6.2%. The telecom giant produces lots of recurring revenue to support that prodigious payout. Last year, Verizon generated $36.9 billion in cash flow from operations, more than enough to cover its capital expenditures ($17.1 billion) and dividend payment ($11.2 billion). The company used its excess free cash flow to strengthen its already solid balance sheet. It's putting some of that balance sheet strength to use to buy Frontier Communications in a $20 billion all-cash deal that should close in the next year. That acquisition will bolster its fiber network and should deliver at least $500 million in annual cost savings. Verizon also continues to invest heavily in organic capital projects to maintain and expand its broadband and mobile networks. These investments should grow the company's earnings and cash flow in the future. Verizon's increasing earnings should enable it to continue raising its dividend. It delivered its 18th consecutive annual dividend increase late last year, a move that maintained the longest current payout-hiking streak in the U.S. telecom sector. The Dow Jones Industrial Index can be a great place for investors to look for high-quality dividend stocks. Chevron, Johnson & Johnson, and Verizon have certainly been elite dividend payers over the years. With yields that are well above the market average and more dividend growth ahead, all three are great Dow stocks to buy for passive income in 2025 and beyond. Before you buy stock in Chevron, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Chevron wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $640,662!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $814,127!* Now, it's worth noting Stock Advisor's total average return is 963% — a market-crushing outperformance compared to 168% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Matt DiLallo has positions in Chevron, Johnson & Johnson, and Verizon Communications. The Motley Fool has positions in and recommends Chevron. The Motley Fool recommends Johnson & Johnson and Verizon Communications. The Motley Fool has a disclosure policy. Generating Passive Income: 3 Top Dow Dividend Stocks to Buy for 2025 and Beyond was originally published by The Motley Fool
